Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611882 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
A Phase 2 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT02611882 is a Phase 2 study that has completed, run by Thomas Hope. The registered enrollment target is 225 participants.
The verdict
NCT02611882, a Phase 2 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy, patients with biochemical recurrence and patients with castrate resistant prostate cancer.
Interventions
- DRUG Ga-68 labeled HBED-CC PSMA
- DEVICE Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)
- DEVICE Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2016-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611882
The ClinicalTrials.gov registry entry for NCT02611882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ga-68 labeled HBED-CC PSMA is the first listed.
NCT02611882 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611882 about?
NCT02611882 is a clinical study titled "Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy, patients with biochemical recurrence and patients with castrate res...
What is the current status of trial NCT02611882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2015-12-18. Estimated completion is 2016-10-24.
What interventions are being tested in trial NCT02611882?
The interventions under investigation include: Ga-68 labeled HBED-CC PSMA (DRUG), Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT) (DEVICE), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI) (DEVICE).
Who is sponsoring clinical trial NCT02611882?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.